+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Human Insulin Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 160 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797960
Description Jump to:
The global market value in 2022 was USD 20.2 billion, driven by the rising prevalence of diabetes across the globe. The global human insulin market share is anticipated to grow at a CAGR of 3.4% during the forecast period of 2023-2031 to achieve a value of USD 27.3 billion by 2031.

Human Insulin: Introduction

Human insulin, a bioengineered version of the hormone produced by the pancreas, plays a vital role in regulating blood sugar levels in people with diabetes. It is widely used in the management of both type 1 and type 2 diabetes, helping patients maintain optimal blood glucose levels and prevent complications arising from hyperglycaemia. The global human insulin market comprises various types of insulin, including rapid-acting, short-acting, intermediate-acting, long-acting, and pre-mixed insulin formulations.

Key Trends in the Human Insulin Market

Some key trends of the market are as follows:
  • Development of novel insulin analogs: The introduction of new insulin analogs, such as ultra-rapid-acting and ultra-long-acting insulin, has provided patients with improved glycaemic control and flexibility in dosing schedules, driving market growth
  • Advancements in insulin delivery devices: The development of innovative insulin delivery devices, such as insulin pens, pumps, and inhalers, has improved patient adherence and satisfaction, contributing to market expansion
  • Increasing focus on diabetes prevention and management: Growing awareness of the importance of early diagnosis, prevention, and effective management of diabetes has resulted in higher demand for human insulin and related products

Market Segmentations

Market Breakup by Product

  • Drugs
  • Delivery Device

Market Breakup by Type

Biosimilars

  • Long Acting
  • Rapid Acting
  • Pre-Mixed

Delivery Device

  • Intermediate-Acting
  • Short Acting
  • Pre-Mixed

Market by Brand

HI Analogs and Biosimilars

  • NovoRapid/Novolog
  • Lantus
  • Humalog
  • Other Brands

HI Biologics

  • Insuman
  • Humulin
  • Actrapid, Insulatard, and Mixtard
  • Others Brands

Market Breakup by Delivery Device

Pens

  • Disposable Pens
  • Reusable Pens
  • Syringes

Pen Needles

  • Standard Pen Needles
  • Safety Pen Needles
  • Others

Market Breakup by Application

  • Type I Diabetes
  • Type II Diabetes

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Market by Region


North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Human Insulin Market Scenario

The global human insulin market has experienced significant growth over recent years, driven by factors such as the rising prevalence of diabetes, an aging population, and growing awareness of the importance of effective diabetes management. Additionally, advancements in insulin delivery devices, the development of novel insulin analogs, and supportive regulatory policies have contributed to the market's expansion.

North America: The largest market for human insulin, driven by factors such as the high prevalence of diabetes, advanced healthcare infrastructure, and a strong focus on research and development.

Europe: The second-largest market, with increasing demand for human insulin due to a growing awareness of the importance of diabetes management and a supportive regulatory framework.

Asia Pacific: Expected to witness the highest growth rate due to factors such as a rapidly aging population, increasing prevalence of diabetes, and growing investments in healthcare infrastructure.

Human Insulin Market: Competitor Landscape

  • Nova Nordisk A/S
  • Biocon Limited
  • Sanofi S.A
  • Pfizer Inc
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Tonghua Dongbao Pharmaceutical Co. Ltd
  • Wockhardt
  • Julphar (Gulf Pharmaceutical Industries)
  • The United Laboratories International Holdings Limited
  • Ypsomed AG
  • Biodel Inc.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Diabetes Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Diabetes Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Diabetes Epidemiology (2016-2031)
5.3 Europe Diabetes Epidemiology (2016-2031)
5.4 Asia-Pacific Diabetes Epidemiology (2016-2031)
5.5 Latin America Diabetes Epidemiology (2016-2031)
5.6 Middle East & Africa Diabetes Epidemiology (2016-2031)
6 Global Human Insulin Market Overview
6.1 Global Human Insulin Market Historical Value (2016-2022)
6.2 Global Human Insulin Market Forecast Value (2023-2031)
7 Global Human Insulin Market Landscape
7.1 Global Human Insulin Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Human Insulin Product Landscape
7.2.1 Analysis by Product Type
7.2.2 Analysis by Distribution Channel
7.2.3 Analysis by Applications
8 Human Insulin Market Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Human Insulin Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Human Insulin Market Segmentation
11.1 Global Human Insulin Market by Product
11.1.1 Market Overview
11.1.2 Drugs
11.1.3 Delivery Device
11.2 Global Human Insulin Market by Type
11.2.1 Market Overview
11.2.2 Biosimilars
11.2.2.1 Long Acting
11.2.2.2 Rapid Acting
11.2.2.3 Pre-Mixed
11.2.3 Delivery Device
11.2.3.1 Intermediate-Acting
11.2.3.2 Short Acting
11.2.3.3 Pre-Mixed
11.3 Global Human Insulin Market by Brand
11.3.1 Market Overview
11.3.2 HI Analogs and Biosimilars
11.3.2.1 NovoRapid/Novolog
11.3.2.2 Lantus
11.3.2.3 Humalog
11.3.2.4 Other Brands
11.3.3 HI Biologics
11.3.3.1 Insuman
11.3.3.2 Humulin
11.3.3.3 Actrapid, Insulatard, and Mixtard
11.3.3.4 Others Brands
11.4 Global Human Insulin Market by Delivery Device
11.4.1 Market Overview
11.4.2 Pens
11.4.2.1 Disposable Pens
11.4.2.2 Reusable Pens
11.4.3 Syringes
11.4.4 Pen Needles
11.4.4.1 Standard Pen Needles
11.4.4.2 Safety Pen Needles
11.4.5 Others
11.5 Global Human Insulin Market by Application
11.5.1 Market Overview
11.5.1.1 Type I Diabetes
11.5.1.2 Type II Diabetes
11.6 Global Human Insulin Market by Distribution Channel
11.6.1 Market Overview
11.6.1.1 Hospital Pharmacy
11.6.1.2 Retail Pharmacy
11.6.1.3 Others
11.7 Global Human Insulin Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.3 Europe
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Human Insulin Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Human Insulin Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Human Insulin Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Human Insulin Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Human Insulin Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
22.1.5 Others
23 Supplier Landscape
23.1 Nova Nordisk A/S
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Biocon Limited
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Sanofi S.A.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Pfizer Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Eli Lilly and Company
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Boehringer Ingelheim International GmbH
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Tonghua Dongbao Pharmaceutical Co. Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Wockhardt
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Julphar (Gulf Pharmaceutical Industries)
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 The United Laboratories International Holdings Limited
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Ypsomed AG
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Biodel Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
24 Global Human Insulin Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Nova Nordisk A/S
  • Biocon Limited
  • Sanofi S.A.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Tonghua Dongbao Pharmaceutical Co. Ltd.
  • Wockhardt
  • Julphar (Gulf Pharmaceutical Industries)
  • The United Laboratories International Holdings Limited
  • Ypsomed AG
  • Biodel Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages160
PublishedMay 2023
Forecast Period2023 - 2031
Estimated Market Value ( USD ) in 2023 $ 20.9 Billion
Forecasted Market Value ( USD ) by 2031 $ 27.3 Billion
Compound Annual Growth Rate3.4%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Global Insulin Pens Market Report and Forecast 2023-2031 - Product Image

Global Insulin Pens Market Report and Forecast 2023-2031

  • Report
  • 160 Pages
  • Global
From
Human Insulin Market Report by Product Type (Drugs, Delivery Devices), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Retail Stores, and Others), Disease Type (Type I Diabetes, Type II Diabetes), and Region 2024-2032 - Product Image

Human Insulin Market Report by Product Type (Drugs, Delivery Devices), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Retail Stores, and Others), Disease Type (Type I Diabetes, Type II Diabetes), and Region 2024-2032

  • Report
  • 149 Pages
  • Global
From
Human Insulin Market Forecasts from 2023 to 2028 - Product Image

Human Insulin Market Forecasts from 2023 to 2028

  • Report
  • 144 Pages
  • Global
From
Human Insulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Human Insulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 141 Pages
  • Global
Global Smart Insulin Pens Market Report and Forecast 2023-2031 - Product Image

Global Smart Insulin Pens Market Report and Forecast 2023-2031

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.